MGX (Metagenomi Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by MGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Pamela Wapnick | Chief Financial Officer | Sell | — | — |
| 2026-09-10 | Matthew Wein | See Remarks | Sell | — | — |
| 2026-09-10 | Jian Irish | See Remarks | Sell | — | — |
| 2026-06-11 | ERIC BJERKHOLT | Director | A | — | — |
| 2026-06-11 | Laurence Reid | Director | A | — | — |
| 2026-06-11 | Willard H Dere | Director | A | — | — |
| 2026-06-11 | Juergen Eckhardt | Director | A | — | — |
| 2026-06-10 | Matthew Wein | See Remarks | Sell | — | — |
| 2026-06-10 | Pamela Wapnick | Chief Financial Officer | Sell | — | — |
| 2026-06-10 | Jian Irish | See Remarks | Sell | — | — |
| 2026-04-03 | Jian Irish | See Remarks | A | — | — |
| 2026-04-03 | Matthew Wein | See Remarks | A | — | — |
| 2026-04-03 | Pamela Wapnick | Chief Financial Officer | A | — | — |
| 2026-03-09 | Pamela Wapnick | Chief Financial Officer | Sell | — | — |
| 2026-03-09 | Matthew Wein | See Remarks | Sell | — | — |
| 2026-03-09 | Jian Irish | Chief Executive Officer | MIXED | — | — |
| 2025-12-08 | Pamela Wapnick | Chief Financial Officer | Sell | — | — |
| 2025-12-08 | Jian Irish | Chief Executive Officer | Sell | — | — |
| 2025-12-08 | Matthew Wein | See Remarks | Sell | — | — |
| 2025-12-08 | Brian C. Thomas | Director | Sell | — | — |
| 2025-12-01 | Brian C. Thomas | Director | Sell | — | — |
| 2025-12-01 | Pamela Wapnick | Chief Financial Officer | MIXED | — | — |
| 2025-12-01 | Jian Irish | Chief Executive Officer | MIXED | — | — |
| 2025-12-01 | Matthew Wein | See Remarks | MIXED | — | — |
| 2025-09-02 | Laurence Reid | Director | A | — | — |
| 2025-06-12 | Juergen Eckhardt | Director | A | — | — |
| 2025-06-12 | Willard H Dere | Director | A | — | — |
| 2025-06-12 | ERIC BJERKHOLT | Director | A | — | — |
| 2025-06-09 | Matthew Wein | See Remarks | Sell | — | — |
| 2025-06-09 | Pamela Wapnick | Chief Financial Officer | Sell | — | — |
| 2025-06-09 | Sarah B. Noonberg | Chief Medical Officer | Sell | — | — |
| 2025-06-09 | Jian Irish | See Remarks | Sell | — | — |
| 2025-06-09 | Brian C. Thomas | Chief Executive Officer | Sell | — | — |
| 2025-04-03 | Sarah B. Noonberg | Chief Medical Officer | A | — | — |
| 2025-04-03 | Jian Irish | See Remarks | A | — | — |
| 2025-04-03 | Pamela Wapnick | Chief Financial Officer | A | — | — |
| 2025-04-03 | Brian C. Thomas | Chief Executive Officer | A | — | — |
| 2025-04-03 | Matthew Wein | See Remarks | A | — | — |
| 2025-03-07 | Matthew Wein | See Remarks | Sell | — | — |
| 2025-03-07 | Pamela Wapnick | Chief Financial Officer | Sell | — | — |
| 2025-02-05 | ERIC BJERKHOLT | Director | A | — | — |
| 2024-12-06 | Pamela Wapnick | Chief Financial Officer | Sell | — | — |
| 2024-09-06 | Pamela Wapnick | Chief Financial Officer | Sell | — | — |
| 2024-04-03 | Willard H Dere | Director | A | — | — |
| 2024-04-03 | Sarah B. Noonberg | Chief Medical Officer | A | — | — |
| 2024-04-03 | Luis Borges | Chief Scientific Officer | A | — | — |
| 2024-04-03 | Sebastian Bernales | Director | A | — | — |
| 2024-04-03 | Simren Delaney | See Remarks | A | — | — |
| 2024-04-03 | Matthew Wein | See Remarks | A | — | — |
| 2024-04-03 | Simon Harnest | See Remarks | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,951,480 | — |
| — | Director | 2,666,290 | — |
| — | Chief Executive Officer | 2,510,960 | — |
| — | See Remarks | 670,246 | — |
| — | Chief Financial Officer | 208,491 | — |
| — | See Remarks | 126,491 | — |
| — | See Remarks | 122,664 | — |
| — | Chief Medical Officer | 109,135 | — |
| — | 10%+ Owner | 100,000 | — |
| — | See Remarks | 93,892 | — |
| — | Chief Scientific Officer | 69,316 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MGX quote page; the site-wide leaderboard is on the insider transactions hub.